Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Imatinib Mesylate 26Sunitinib 22nilotinib 12ripretinib 11regorafenib 7avapritinib 7tanespimycin 2pexidartinib 2masitinib 2famitinib 2Midazolam 2IDRX-42 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2umbralisib 1trastuzumab deruxtecan 1trametinib 1tinostamustine 1spartalizumab 1ribociclib 1repaglinide 1ponatinib 1perifosine 1pembrolizumab 1olverembatinib 1olaratumab 1motesanib diphosphate 1dabrafenib 1cediranib 1binimetinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastrointestinal Stromal Tumors × TAS-116 × Clear all
NCT05245968 2026-01-20

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

Taiho Pharmaceutical Co., Ltd.

Phase 1 Active not recruiting
78 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡